Image 12_Serum neuritin as a predictive biomarker of early neurological deterioration and poor prognosis after spontaneous intracerebral hemorrhage: a prospective cohort study.tif by Yanwen Xu (663813)

“…END was defined as a decrease of ≥2 points in the GCS score within 24 h of admission. …”

Image 11_Serum neuritin as a predictive biomarker of early neurological deterioration and poor prognosis after spontaneous intracerebral hemorrhage: a prospective cohort study.tiff by Yanwen Xu (663813)

“…END was defined as a decrease of ≥2 points in the GCS score within 24 h of admission. …”

Image 8_Serum neuritin as a predictive biomarker of early neurological deterioration and poor prognosis after spontaneous intracerebral hemorrhage: a prospective cohort study.tif by Yanwen Xu (663813)

“…END was defined as a decrease of ≥2 points in the GCS score within 24 h of admission. …”

Image 1_Serum neuritin as a predictive biomarker of early neurological deterioration and poor prognosis after spontaneous intracerebral hemorrhage: a prospective cohort study.tif by Yanwen Xu (663813)

“…END was defined as a decrease of ≥2 points in the GCS score within 24 h of admission. …”

Table 1_Serum neuritin as a predictive biomarker of early neurological deterioration and poor prognosis after spontaneous intracerebral hemorrhage: a prospective cohort study.doc by Yanwen Xu (663813)

“…END was defined as a decrease of ≥2 points in the GCS score within 24 h of admission. …”

Image 5_Serum neuritin as a predictive biomarker of early neurological deterioration and poor prognosis after spontaneous intracerebral hemorrhage: a prospective cohort study.tif by Yanwen Xu (663813)

“…END was defined as a decrease of ≥2 points in the GCS score within 24 h of admission. …”

Image 13_Serum neuritin as a predictive biomarker of early neurological deterioration and poor prognosis after spontaneous intracerebral hemorrhage: a prospective cohort study.tif by Yanwen Xu (663813)

“…END was defined as a decrease of ≥2 points in the GCS score within 24 h of admission. …”

Table6_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Renal function and risk of dementia: a Mendelian randomization study by Haowen Huang (1430386)

“…</p> <p>The findings indicate a significant correlation between each unit increase in cystatin C-based estimated glomerular filtration rate (eGFR-cys) levels was significantly associated with a reduction in the incidence of late-onset Alzheimer’s disease (LOAD) (IVW: OR = 0.35, 95% CI: 0.13–0.91, <i>p</i> = 0.031). …”

Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses by Jing Wang (6206297)

“…However, how global land use changes impact soil N supply and potential N loss remains elusive. By compiling a global data set of 1,782 paired observations from 185 publications, we show that land use conversion from natural to managed ecosystems significantly reduced NNM by 7.5% (−11.5, −2.8%) and increased NN by 150% (86, 194%), indicating decreasing N availability while increasing potential N loss through denitrification and nitrate leaching. …”

Table 1_Efficacy and safety of combination of frankincense and botulinum toxin in the treatment of blepharospasm: a protocol for a single-centre, open-label, randomized, controlled... by Shiyuan Gong (22754579)

“…Symptom improvement is defined as a decrease of one point or more in the Jankovic Rating Scale severity score compared to baseline in patients with BSP. …”

Supplementary file 1_Phase angle as a predictor of prolonged length of hospital stay and adverse outcomes in elderly medical inpatients: a retrospective cohort study.docx by Jia Liu (41593)

“…Adverse event rates across the PhA tertiles (T1–T3) were 32.9%, 18.6%, and 5.6%, respectively, indicating a significant decrease in event incidence as PhA values increased. …”

Table 1_A population database analysis to describe the residual burden of varicella in Italy—a high vaccination coverage area—from 2004 to 2022.docx by Elisa Barbieri (115023)

“…In the Veneto Region, following the implementation of VV in 2006, the IR significantly decreased by 20.5 annually (95% CI: −23.4, −17.5), ranging from 50.2 per 1,000 person-years in 2006 to 1.2 per 1,000 person-years in 2022.…”